Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Antiviral Res. 2016 Apr 6;131:19–25. doi: 10.1016/j.antiviral.2016.03.015

Table 1. Activity of select Series 1, 2, and 3 compounds in the replicon and CPEassays.

The replicon assay was performed with APC126-E RSV replicon cells as described in the text. CPE assays were performed with Hep2 cells infected with RSV A2, RSV A Long, and RSV B Washington. Cytotoxicity was also determined in uninfected host cells. Series 1 and 2 are depicted in Panel A; Series 3 compounds are depicted in Panel B.

A. Series 1 Activity (μM) Series 2 Activity (μM)
graphic file with name nihms780853u1.jpg graphic file with name nihms780853u2.jpg graphic file with name nihms780853u3.jpg graphic file with name nihms780853u4.jpg graphic file with name nihms780853u5.jpg
BRD9101 BRD3969 BRD65768 BRD4517 BRD9259
Replicon EC50 4.3 4.2 4.3 10.6 4.4
RSV A2 EC50 1.7/2.8* 1.6/3.3* 2.9/4.4* 1.3/1.2* 1.6/1.4*
RSV A2 CC50 > 100/>100* 54/56* 59/64* 29/22* 31/60*
RSV Long EC50 1.7 3.9 7.5 1.6 1.6
RSV B EC50 > 50 > 50 > 50 5.5 6.8
B. Series 3 Activity (μM)
graphic file with name nihms780853u6.jpg graphic file with name nihms780853u7.jpg graphic file with name nihms780853u8.jpg
BRD3482 BRD6801 BRD5449
Replicon EC50 7.2 7.3 4.9
RSV A2 EC50 21/26.8* 16.9/46.7* 13.7/10.3*
RSV A2 CC50 > 100/> 100* 95.7/> 100* 60/99*
RSV Long EC50 1.0 5.8 6.8
RSV B EC50 4.7 11.9 > 50
*

Activity of resynthesized compounds.